Who makes ALXN1840 Enteric-coated Tablet?

ALXN1840 Enteric-coated Tablet is developed by Alexion Pharmaceuticals, Inc..

What development phase is ALXN1840 Enteric-coated Tablet in?

ALXN1840 Enteric-coated Tablet is in Phase 1.

Last reviewed 2026-04-23 · How we verify

ALXN1840 Enteric-coated Tablet

Alexion Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	ALXN1840 Enteric-coated Tablet
Also known as	WTX101 (formerly), Bis-choline tetrathiomolybdate, Tiomolibdate choline
Sponsor	Alexion Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants (PHASE1)
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. (PHASE1)
Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults (PHASE1)
A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ALXN1840 Enteric-coated Tablet CI brief — competitive landscape report
ALXN1840 Enteric-coated Tablet updates RSS · CI watch RSS
Alexion Pharmaceuticals, Inc. portfolio CI